Lugli, Alessandro; Zlobec, Inti; Berger, Martin D.; Kirsch, Richard; Nagtegaal, Iris D (2021). Tumour budding in solid cancers. Nature reviews. Clinical oncology, 18(2), pp. 101-115. Springer Nature 10.1038/s41571-020-0422-y
![[img]](https://boris.unibe.ch/style/images/fileicons/text.png) |
Text
s41571-020-0422-y.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (2MB) | Request a copy |
Tumour budding is an emerging prognostic biomarker in colorectal cancer (CRC) and other solid cancers. Tumour buds are usually defined as isolated single cancer cells or clusters of up to four cancer cells located at the invasive tumour front. The prognostic value of tumour budding is now supported by a large body of evidence, whereas the utility of this phenotype as a predictive biomarker remains under investigation. The application of tumour budding indices in clinical practice requires a standardized scoring system that can be tailored to specific tumour types and clinical scenarios. In the context of CRC, tumour budding can be assessed according to the method agreed at the International Tumour Budding Consensus Conference (ITBCC) in 2016. Using the ITBCC scoring system, tumour budding is an independent predictor of lymph node metastasis in patients with pT1 CRC and of unfavourable survival in patients with stage II colon cancer. Regardless of the clinical scenario or tumour type, the assertion that 'the more tumour buds, the worse the clinical outcome' applies. In this Review, we provide an overview of tumour budding in solid cancers, highlighting the molecular and biological aspects of this phenomenon, including its associations with epithelial-mesenchymal transition and features of the tumour microenvironment. We also describe the available evidence demonstrating the value of tumour budding as a biomarker across various solid cancers.
Item Type: |
Journal Article (Review Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Service Sector > Institute of Pathology 04 Faculty of Medicine > Service Sector > Institute of Pathology > Translational Research Unit 04 Faculty of Medicine > Service Sector > Institute of Pathology > Clinical Pathology 04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology |
UniBE Contributor: |
Lugli, Alessandro, Zlobec, Inti, Berger, Martin Dave |
Subjects: |
500 Science > 570 Life sciences; biology 600 Technology > 610 Medicine & health |
ISSN: |
1759-4782 |
Publisher: |
Springer Nature |
Language: |
English |
Submitter: |
Rebeka Gerber |
Date Deposited: |
12 Nov 2020 12:06 |
Last Modified: |
05 Dec 2022 15:41 |
Publisher DOI: |
10.1038/s41571-020-0422-y |
PubMed ID: |
32901132 |
BORIS DOI: |
10.7892/boris.147566 |
URI: |
https://boris.unibe.ch/id/eprint/147566 |
Actions (login required)
 |
Edit item |